Lead Product(s): OLX301D
Therapeutic Area: Ophthalmology Product Name: OLX301D
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: OliX Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2020
Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.